Back to top
more

AnaptysBio (ANAB)

(Delayed Data from NSDQ)

$18.87 USD

18.87
401,012

-0.40 (-2.08%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $18.83 -0.04 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

by Zacks Equity Research

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?

by Zacks Equity Research

Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results

by Zacks Equity Research

Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.

Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024

by Zacks Equity Research

Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.

Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?

by Zacks Equity Research

Here is how Acadia Healthcare (ACHC) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 69.4% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why

by Zacks Equity Research

Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.

Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug

by Zacks Equity Research

Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

by Zacks Equity Research

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

by Zacks Equity Research

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment

by Zacks Equity Research

Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.

Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug

by Zacks Equity Research

Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

by Zacks Equity Research

Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.

Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -15.91% and 6.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -13.58% and 24.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -51.92% and 65.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?